Literature DB >> 21305704

Estrogen receptor-positive breast cancer: a multidisciplinary challenge.

Wilbert Zwart1, Vasiliki Theodorou, Jason S Carroll.   

Abstract

Estrogen receptor (ER)-positive breast cancer research is an ideal example of how systems biology can be applied to better understand a specific clinical issue. By integrating vast data sets from tumor-derived expression arrays, genome-wide transcription factor/chromatin interactions, proteomics and computational analyses, we may better understand the concept of breast cancer development, heterogeneity, and its treatment. Resistance to endocrine treatment, such as anti-estrogens, often occurs and systems biology may prove to be a valuable asset in tailoring treatment for each patient. In such a multidisciplinary setup, it is essential to try and connect these massive data streams with the known pathological background and cell biology. In this review, we describe the current status of such studies and the challenges that are to be met in order to fully understand the concept of anti-estrogen resistance from a holistic perspective.
Copyright © 2010 John Wiley & Sons, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21305704     DOI: 10.1002/wsbm.109

Source DB:  PubMed          Journal:  Wiley Interdiscip Rev Syst Biol Med        ISSN: 1939-005X


  12 in total

Review 1.  Integration of proteomics into systems biology of cancer.

Authors:  S Hanash; M Schliekelman; Q Zhang; A Taguchi
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2012-03-08

2.  Comparative Effectiveness of Surgical Options for Patients with Ductal Carcinoma In Situ: An Instrumental Variable Approach.

Authors:  Lewei Duan; Aniket A Kawatkar
Journal:  Perm J       Date:  2018

Review 3.  A review of prognostic and predictive biomarkers in breast cancer.

Authors:  Elaheh Tarighati; Hadi Keivan; Hojjat Mahani
Journal:  Clin Exp Med       Date:  2022-01-15       Impact factor: 3.984

4.  A kinetic model identifies phosphorylated estrogen receptor-α (ERα) as a critical regulator of ERα dynamics in breast cancer.

Authors:  Dan Tian; Natalia M Solodin; Prashant Rajbhandari; Kelsi Bjorklund; Elaine T Alarid; Pamela K Kreeger
Journal:  FASEB J       Date:  2015-02-03       Impact factor: 5.191

5.  Proteomic snapshot of breast cancer cell cycle: G1/S transition point.

Authors:  Milagros J Tenga; Iulia M Lazar
Journal:  Proteomics       Date:  2013-01       Impact factor: 3.984

6.  Interaction of 14-3-3 proteins with the estrogen receptor alpha F domain provides a drug target interface.

Authors:  Ingrid J De Vries-van Leeuwen; Daniel da Costa Pereira; Koen D Flach; Sander R Piersma; Christian Haase; David Bier; Zeliha Yalcin; Rob Michalides; K Anton Feenstra; Connie R Jiménez; Tom F A de Greef; Luc Brunsveld; Christian Ottmann; Wilbert Zwart; Albertus H de Boer
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-15       Impact factor: 11.205

7.  miRNA-34b as a tumor suppressor in estrogen-dependent growth of breast cancer cells.

Authors:  Yee-Ming Lee; Jen-Yi Lee; Chao-Chi Ho; Qi-Sheng Hong; Sung-Liang Yu; Chii-Ruey Tzeng; Pan-Chyr Yang; Huei-Wen Chen
Journal:  Breast Cancer Res       Date:  2011-11-23       Impact factor: 6.466

8.  Tissue-Specific Effects of Loss of Estrogen during Menopause and Aging.

Authors:  Korinna Wend; Peter Wend; Susan A Krum
Journal:  Front Endocrinol (Lausanne)       Date:  2012-02-08       Impact factor: 5.555

9.  The atypical ubiquitin ligase RNF31 stabilizes estrogen receptor α and modulates estrogen-stimulated breast cancer cell proliferation.

Authors:  J Zhu; C Zhao; A Kharman-Biz; T Zhuang; P Jonsson; N Liang; C Williams; C-Y Lin; Y Qiao; K Zendehdel; S Strömblad; E Treuter; K Dahlman-Wright
Journal:  Oncogene       Date:  2014-01-20       Impact factor: 9.867

10.  MART-10, a New Generation of Vitamin D Analog, Is More Potent than 1α,25-Dihydroxyvitamin D(3) in Inhibiting Cell Proliferation and Inducing Apoptosis in ER+ MCF-7 Breast Cancer Cells.

Authors:  Kun-Chun Chiang; Chun-Nan Yeh; Shin-Cheh Chen; Shih-Che Shen; Jun-Te Hsu; Ta-Sen Yeh; Jong-Hwei S Pang; Li-Jen Su; Masashi Takano; Atsushi Kittaka; Horng-Heng Juang; Tai C Chen
Journal:  Evid Based Complement Alternat Med       Date:  2012-12-11       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.